Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

Last updated: August 13, 2024
Sponsor: University of Pennsylvania
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alzheimer's Disease

Dementia

Memory Loss

Treatment

AV-1451

Clinical Study ID

NCT05658913
850679
  • Ages 18-120
  • All Genders

Study Summary

To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Enrolled in MPC study (Protocol 850160 at UPenn; Protocol 2022P002447 at MGH).

  2. Reliable study partner to accompany participant to the PET/CT scan

  3. A brain MRI must be performed within 6 months prior to their study AV-1451 TAUPET/CT scan date and be deemed of adequate quality that the scan may be used forstudy analysis, including 3T high-resolution imaging of medial temporal lobestructures.

Exclusion

Exclusion Criteria:

  1. Have any medical or psychiatric conditions that, in the opinion of the investigator,would compromise the subject's safety or successful participation in the study.

  2. Have evidence of structural abnormalities such as major stroke or mass on MRI thatis likely to interfere with analysis of the PET/CT scan.

  3. Inability to tolerate or contraindication to imaging procedures in the opinion of aninvestigator or treating physician.

  4. Have a history of significant ongoing alcohol or substance abuse based on self-report.

  5. Female participants of child-bearing age will not be able to participate in thisstudy, determined by self-report.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: AV-1451
Phase:
Study Start date:
March 14, 2023
Estimated Completion Date:
December 31, 2029

Study Description

This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants. All subjects will already have been enrolled in the MPC Study. For the current protocol, participants will provide informed consent before beginning any study procedures. After screening assessments, participants will undergo PET/CT scan imaging with AV-1451.

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114-2696
    United States

    Active - Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.